Ladenburg Thalmann analyst Aydin Huseynov downgrades Allarity Therapeutics (NASDAQ:ALLR) from Buy to Neutral.
Phase 3 Studies Of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope For Patients With Multidrug-Resistant Infections And Limited Treatment Options
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Pfizer Inc.
